Commercialize and partner successfully in Europe and the Middle East
Dr. Stefan Fraenkel, Executive Vice President, Inceptua Pharma Understand how to commercialize via partnering in Europe and other markets outside…
Read More Insights
The 21st Century Cures Act (21CCA), which came into effect in February 2017, is intended to help accelerate the development of medicines and bring those medicines to patients more quickly.…
Policies on pre-approval access (‘early access’, ‘expanded access’ etc.) have come into focus since the enactment of the US 21st Century Cures Act. Driven by the requirements of the Act,…
News and Press Releases
NEWTOWN, PA., and LUXEMBOURG, Dec 6, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with…
To further strengthen its position as a leading pharmaceutical company and service partner, Inceptua appoints Paul Wituschek as President North America effective 1 January, 2020. Paul will take on the…
Inceptua and Bendalis enter into an exclusive oncology medicine supply agreement for clinical trials
BERLIN / MUNICH – 25 November 2019 – The global pharmaceutical company and service partner Inceptua Group (previously Multipharma GmbH) and Bendalis GmbH – German manufacturer of generic oncology drugs…
